Coming Soon

Feature

Progress

Priority Review Voucher valuation model

Most companies and outlets assume the current value of a priority review voucher based on the last public sale price. I will be creating a model for PRV valuations accounting for number in supply, number expected to be issued, potential purchasers and likelihood of a company selling their voucher.

⁠

Overview of clinical stage assets that may be eligible for priority review vouchers

⁠

Overview of potential purchasers of priority review vouchers

⁠

FDA CRL Dashboard

⁠

No. of PRVs held by each company

There are no rows in this table

⁠